tailieunhanh - Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Visceral metastases account for 48–67% of metastatic breast cancer (MBC) patients and presage a worse overall survival. Previous study suggested potential effect of nab-paclitaxel on patients with visceral metastases subgroups. This phase II trial was conducted to explore the efficacy and safety of nab-paclitaxel in such a high-risk group of patients. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN